Sublingual mucosa: A new vaccination route for systemic and mucosal immunity

Cytokine

Volumn 54, Issue 1, 2011, Pages 1-5

  Kweon, Mi Na ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

CCR7; Dendritic Cells; Influenza; Mucosa; Sublingual

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; VIRUS RNA; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONDYLOMA ACUMINATUM; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LYMPH FLOW; MUCOSAL IMMUNITY; NEEDLESTICK INJURY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; SUBLINGUAL GLAND; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; WART VIRUS;

ADMINISTRATION, SUBLINGUAL; ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL19; DENDRITIC CELLS; ESCHERICHIA COLI; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LYMPH NODES; MICE; MOUTH MUCOSA; MUCOUS MEMBRANE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, CCR7; T-LYMPHOCYTES; VACCINES;

ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE;

EID: 79952067654     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.12.014     Document Type: Review

References (36)

1. McGhee J.R., Kiyono H. The mucosal immune system. Fundamental Immunology 2004, 965-1020. Lippincott Williams & Wilkins, Philadelphia. W.E. Paul (Ed.).
2. Boyaka P.N., McGhee J.R., Czerkinsky C., Mestecky J. Mucosal vaccines: An overwiew. Mucosal immunology 2007, 855-874. Elsevier/Academic Press, Amsterdam. 3rd ed.
3. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
4. Russell M.W., Kilian M. Biological activities of IgA. Mucosal immunology 2007, 267-289. Elsevier/Academic Press, Amsterdam. 3rd ed.
5. Nair P.N., Schroeder H.E. Local immune response to repeated topical antigen application in the simian labial mucosa. Infect Immun 1983, 41:399-409.
6. Quiding M., Nordstrom I., Kilander A., Andersson G., Hanson L.A., Holmgren J., et al. Intestinal immune responses in humans Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991, 88:143-148.
7. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997, 65:1387-1394.
8. Jertborn M., Nordstrom I., Kilander A., Czerkinsky C., Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun 2001, 69:4125-4128.
9. Johansson E.L., Wassen L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001, 69:7481-7486.
10. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000, 6:1403-1406.
11. Brandtzaeg P., Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004, 25:570-577.
12. Suzuki K., Fagarasan S. How host-bacterial interactions lead to IgA synthesis in the gut. Trends Immunol 2008, 29:523-531.
13. Yuki Y., Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 2003, 13:293-310.
14. Kunkel E.J., Butcher E.C. Plasma-cell homing. Nat Rev Immunol 2003, 3:822-829.
15. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
16. Kweon M.N., Yamamoto M., Watanabe F., Tamura S., Van Ginkel F.W., Miyauchi A., et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 2002, 186:1261-1269.
17. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. N Engl J Med 2004, 350:896-903.
18. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165:4778-4782.
19. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. 2005, 73:6892-6902.
20. Kildsgaard J., Brimnes J., Jacobi H., Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 2007, 98:366-372.
21. Brimnes J., Kildsgaard J., Jacobi H., Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007, 37:488-497.
22. Noonan P.K., Benet L.Z. Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol 1985, 55:184-187.
23. Cleary J.F. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997, 24:S16:13-9.
24. Agostinis F., Tellarini L., Canonica G.W., Falagiani P., Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005, 60:133.
25. Grosclaude M., Bouillot P., Alt R., Leynadier F., Scheinmann P., Rufin P., et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002, 129:248-253.
26. Olaguibel J.M., Alvarez Puebla M.J. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005, 15:9-16.
27. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Cuburu N., Czerkinsky C., et al. CCR7-CCL19/CCL21 regulated dendritic cells are responsible for the effectiveness of sublingual vaccination. J Immunol 2009, 182:6851-6860.
28. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25:8598-8610.
29. - effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2006, 291:G267-G274.
30. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008, 105:1644-1649.
31. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009, 183:7851-7859.
32. Bowman E.P., Kuklin N.A., Youngman K.R., Lazarus N.H., Kunkel E.J., Pan J., et al. The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J Exp Med 2002, 195:269-275.
33. Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998, 72:8220-8229.
34. Senel S., Kremer M., Nagy K., Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol 2001, 2:175-186.
35. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
36. Razafindratsita A., Saint-Lu N., Mascarell L., Berjont N., Bardon T., Betbeder D., et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007, 120:278-285.